Clene Nanomedicine Aims to be the 'Gold Standard' in Neurodegenerative Disease – BioBuzz
Clene Nanomedicine Aims to be the ‘Gold Standard’ in Neurodegenerative Disease Clene Nanomedicine, one of Maryland’s Future 2020 companies, closed a merger with Tottenham Acquisition I Limited that provided the company with a slot on the Nasdaq Exchange and $31.9 million that will be used to advance the company’s gold nanocrystal-based treatment for neurodegenerative diseases. Clene is developing a new class of drugs called bioenergetic nanotherapeutics that harnesses the properties of gold nanocrystals, which are used to amplify bioenergetic reactions in patients in order to drive in...